Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bamocaftor Triple Combo PK/Safety in Pediatric CF (6-11 Years)
NCT03633526Phase 3Terminated
- Sponsor
- Vertex Pharmaceuticals
- Start
- Aug 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bamocaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Primary endpoints: Maximum Observed Concentration at Day 15, Observed Pre-Dose Concentration at Day 15 and 1 more. Started Aug 2018; status: terminated.
02
Drugs
bamocaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03633526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03633526.